REGN - Latest News

Regeneron Pharmaceuticals, Inc. (REGN), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $98.82B. Trailing twelve-month P/E ratio is 20.17. Beta to the broader market is 0.24.

The article list below shows the most recent REGN headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent REGN Headlines

4 Dividend Stocks Retirees Can Buy Before They Go Ex-Dividend in the Week Ahead

247wallst.com - Nov 15, 2026

Four Nasdaq payers hit their ex-dividend dates within two trading days, and one wrong move on timing forfeits the check. Which ones have the cash flo

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

fool.com - Nov 14, 2026

Regeneron sells 16 products, and they have helped revenue climb in recent years. The company's leading products delivered record revenue in the third

Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by AlphaCore Capital LLC

defenseworld.net - Nov 13, 2026

AlphaCore Capital LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 133.

POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms

globenewswire.com - Nov 12, 2026

Data presented today for the first time at the American Autonomic Society (AAS) annual meeting POTS (postural orthostatic tachycardia syndrome) is a d

REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock?

zacks.com - Nov 12, 2026

Regeneron's strong Eylea HD and Dupixent sales, expanding oncology portfolio and promising pipeline fuel growth prospects as Eylea faces intensifying

How News Affects REGN Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track REGN's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked REGN news questions

What is the latest REGN news headline?
The most recent REGN headline (Nov 15, 2026) is "4 Dividend Stocks Retirees Can Buy Before They Go Ex-Dividend in the Week Ahead". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
How fresh is the REGN news on this page?
News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
What REGN news moves options pricing?
Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
How can I track unusual REGN options activity related to news?
Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.